Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
Subacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in J...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/2/427 |
id |
doaj-2b391b682225469eb726145002b9bbad |
---|---|
record_format |
Article |
spelling |
doaj-2b391b682225469eb726145002b9bbad2021-01-16T00:01:28ZengMDPI AGMolecules1420-30492021-01-012642742710.3390/molecules26020427Advances in Antiviral Therapy for Subacute Sclerosing PanencephalitisKoichi Hashimoto0Mitsuaki Hosoya1Department of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima 9601295, JapanDepartment of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima 9601295, JapanSubacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in Japan based on fundamental and clinical research findings from our group, with positive therapeutic effects reported in some patients. However, the efficacy of this treatment approach has not been unequivocally established. Hence, development of more effective therapeutic methods using new antiviral agents is urgently needed. This review describes the current status of SSPE treatment and research, highlighting promising approaches to the development of more effective therapeutic methods.https://www.mdpi.com/1420-3049/26/2/427SSPEribavirintherapyantiviral agent |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Koichi Hashimoto Mitsuaki Hosoya |
spellingShingle |
Koichi Hashimoto Mitsuaki Hosoya Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis Molecules SSPE ribavirin therapy antiviral agent |
author_facet |
Koichi Hashimoto Mitsuaki Hosoya |
author_sort |
Koichi Hashimoto |
title |
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis |
title_short |
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis |
title_full |
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis |
title_fullStr |
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis |
title_full_unstemmed |
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis |
title_sort |
advances in antiviral therapy for subacute sclerosing panencephalitis |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2021-01-01 |
description |
Subacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in Japan based on fundamental and clinical research findings from our group, with positive therapeutic effects reported in some patients. However, the efficacy of this treatment approach has not been unequivocally established. Hence, development of more effective therapeutic methods using new antiviral agents is urgently needed. This review describes the current status of SSPE treatment and research, highlighting promising approaches to the development of more effective therapeutic methods. |
topic |
SSPE ribavirin therapy antiviral agent |
url |
https://www.mdpi.com/1420-3049/26/2/427 |
work_keys_str_mv |
AT koichihashimoto advancesinantiviraltherapyforsubacutesclerosingpanencephalitis AT mitsuakihosoya advancesinantiviraltherapyforsubacutesclerosingpanencephalitis |
_version_ |
1724336219240792064 |